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Health Information Technologies 
in Diabetes Management
Yilin Yoshida and Eduardo J. Simoes
Abstract
About 1 in 11 adults worldwide now have diabetes mellitus, 90% of whom have 
type 2 diabetes (T2D). Successful glycemic control helps to prevent and reduce 
complications of T2D, including cardiovascular disease, kidney disease, blind-
ness, neuropathy, and limb amputation, and reduce death related to the disease. 
However, maintaining optimal glycemic control requires ongoing monitoring and 
treatment, which can be costly and challenging. To improve diabetes management, 
the development of innovative self-care strategies is warranted. Advances in health 
information technologies (HITs) have introduced approaches that support effective 
and affordable health-care delivery and patient education. Technologies in mobile, 
computer, e-mail, and Internet approaches have shown evidence in enhancing 
chronic disease management, suggesting great potential for diabetes management 
technologies. In this chapter, we provided an overview of the HITs in use for T2D 
management. We synthesized the latest findings on HITs’ effect in reducing HbA1c 
and managing complications, cardiovascular conditions, in particular. Further, we 
discussed limitations in the current research in this area and implications for future 
research. Last, we presented challenges of applying HITs in T2D management in the 
real-world context and suggested steps to move forward.
Keywords: health information technologies, type 2 diabetes mellitus, 
glycemic control, HbA1c
1. Introduction
Diabetes is the fastest growing chronic condition worldwide. The prevalence of 
people with type 2 diabetes (T2D) is growing in each country [1]. Diabetes is also the 
seventh leading cause of deaths in the world. Around 1.6 million people died due to 
diabetes in 2016 [1]. Higher blood glucose levels also caused an additional 2.2 million 
deaths, by increasing the risks of cardiovascular and other complications such as 
kidney disease, blindness, neuropathy, and limb amputation [2–4]. Successful 
glycemic control can prevent and reduce these complications. However, to maintain 
optimal glycemic control requires ongoing monitoring and treatment, which can 
be costly and challenging [5]. Advances in health information technologies (HITs) 
have introduced approaches that support effective and affordable health-care 
delivery and education. Technologies in mobile, computer, e-mail, and Internet 
approaches have shown evidence in enhancing chronic disease management 
including diabetes management, via supporting provider decision-making (through 
electronic risk assessment, alerts, guidelines, formularies, and prescribing) and 
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facilitating patient self-management (through risk communication, Web portals, 
telemedicine, e-mailing, and secure messaging) [6–8]. In this chapter, we summa-
rized the current findings on HITs in managing T2D, especially on glycemic control 
and CVD risks management. In addition, we discussed limitations in the current 
research in this area and implications for future research. Further, we presented 
challenges of applying HITs in T2D management in the real-world context and 
suggested steps to move forward.
2. The potential of HITs in chronic disease management
HITs include a broad range of technologies, electronic tools, applications, or sys-
tems that provide patient care, information, recommendations, or services for pro-
motion of health and health care [9]. The advantages of using HITs in health care 
have been well documented [10–13]. They have the potential to empower patients 
and support a transition from a role in which the patient is the passive recipient of 
care services to an active role in which the patient is informed, has choices, and is 
involved in the decision-making process [10]. They are also designed to promote 
communication and relationships between clinicians and patients and overcome 
geographical barriers and logistical inconvenience when seeking health-care 
services [11]. In the realm of chronic disease management, a variety of technologies 
have shown their positive effects. For examples, electronic health record system 
provides reminders at the point of care for providers to identify high-priority 
clinical areas for patients with complex chronic illness [14]; telemonitoring system 
provides asthma patients with continuous individualized help in the daily routine 
of asthma self-care [12]; Web-based applications increase knowledge, problem-
solving skills, and social support via an interactive system for patients with cancers 
[13]; mobile technology devices such as personal digital assistants (PDAs) and 
cellular phones enable additional resources to care and change the location of care; 
and mobile phone short message service (SMS) were able to remind patients of 
scheduled visits, deliver test results, and monitor side effects of treatment [15–17]. 
The HIT-enabled self-care keeps evolving and attempts to address more challenging 
health-care issues, such as diabetes management where patients need comprehen-
sive information and ongoing guidance as they work to develop a diverse knowledge 
and skills.
3. HITs in glycemic control among patients with T2D
A growing research attention has been given to evaluate HITs’ impact on dia-
betes management, including the primary management goal, glycemic status, and 
major complications such as cardiovascular conditions. Previous reviews on this 
subject suggested that HITs have the potential to improve these disease outcomes 
[18–23]. However, effect size is specific to the main outcome; glycated hemoglobin 
(HbA1c) varied between studies with reported mean difference ranging from −0.20 
to −0.57% [19–23]. Table 1 presented the synthesized findings from the latest 
systematic reviews. Heitkemper et al. searched randomized control trials (RCTs) 
that studied the effect of HITs on HbA1c among medically underserved patients 
[21]. In this meta-analysis of 10 eligible trials, HITs were associated with significant 
HbA1c reduction at 6 months (pooled standardized difference in mean: −0.36, 95% 
CI −0.53, −0.19) with diminishing but still significant effect at 12 months (pooled 
standardized difference in mean: −0.27, 95% CI −0.49, −0.04). The authors also 
performed analyses by HIT type including computer software without Internet 
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Author, year Objective and 
intervention(s) 
under review
Inclusion 
criteria
Sample HbA1c 
reduction 
(absolute 
difference in 
means)
HbA1c reduction 
(standardized 
difference in 
means and 
Hedges’ g)
CVD risk 
factor 
assessment
Intervention 
period
HIT subgroup analysis Major 
limitations
Yoshida et al., 
2018 [33]
Evaluating of effect 
of HITs on T2D 
glycemic control 
in general T2D 
patients, including 
mobile phone-based 
HITs, Web-based 
HITs, short message/
text, and other HITs
RCTs 
conducted 
from 
1946 to 
December 
2017
34 RCTs (40 
estimation 
points); 3983 
participants 
with T2D
−0.65% (95% CI 
−0.99, −0.64%)
Standard mean 
difference: −0.57 
(95% CI −0.71, 
−0.43);
Hedges’ g: −0.56 
(95% CI −0.70, 
−0.43)
A separate 
analysis 
focusing on 
CVD risk 
factors is 
upcoming
2–12 months Mobile phone-based approaches 
[Hedges’ g = −0.66 (95% CI 
−0.88, −0.45)]; SMS/text [Hedges’ 
g = −0.63 (95% CI −1.07, −0.19)]; 
Web-based [Hedges’ g = −0.48 
(95% CI −0.65, −0.30)]
Did not provide 
analysis at 
different time 
points
Heitkemper 
et al., 2017 [21]
Evaluating of 
effect of HIT 
self-management 
interventions on 
glycemic control 
in medically 
underserved adults 
with diabetes, 
including computer 
software without 
Internet, cellular/
automated 
telephone, Internet-
based HITs, and 
telemedicine/
telehealth
RCTs 
conducted 
from 2000 
to 2015
10 RCTs; 3257 
medically 
underserved 
adults with 
diabetes
Not reported Standard mean 
difference: −0.36, 
95% CI −0.53, 
−0.19 at 6 months 
and −0.27, 95% CI 
−0.49, −0.04 at 
12 months
No Up to 
12 months
Internet-based HITs (standard 
mean difference = −0.50, 95% 
CI −0.69, −0.32 at 6 months and 
−0.87, 95% CI −1.58, −0.21 at 
12 months); cellular/automated 
telephone HITs (standard mean 
difference = −0.26, 95% CI 
−0.49, −0.03 at 6 months and 
not significant at 12 months); 
telehealth (standard mean 
difference = −0.37, 95% CI −0.68, 
−0.06 at 6 months and not 
significant at 12 months)
External validity 
issue (only 
focused on a 
specific patient 
group); mixed 
participants 
with type 1 and 
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Author, year Objective and 
intervention(s) 
under review
Inclusion 
criteria
Sample HbA1c 
reduction 
(absolute 
difference in 
means)
HbA1c reduction 
(standardized 
difference in 
means and 
Hedges’ g)
CVD risk 
factor 
assessment
Intervention 
period
HIT subgroup analysis Major 
limitations
Tao et al., 2017 
[18]
Evacuating 
of effect of 
consumer-oriented 
HITs in diabetes 
management
RCTs 
conducted 
up until July 
2016
18 RCTs; 
participants in 
trials ranged 
from 14 to 1382
Not reported Standard mean 
difference: 
−0.31, 95% CI 
−0.38, −0.23; 
glycemic control 
was significant 
at intervention 
duration of 3, 6, 8, 
9, 12, 15, 30, and 
60 months
No Up to 
60 months
Not reported Lumped 
all types of 
HITs into 
analysis; mixed 
participants 
with type 1 and 
2 diabetes
Faruque et al., 
2017 [20]
Evaluating of effect 
of telemedicine 
on glycemic 
control, including 
broad forms of 
electronic forms 
communication.
RCTs 
conducted 
from 
1946 to 
November 
2015
111 RCTs; 
23,648 
participants 
with diabetes
−0.57% (95% CI 
−0.74, −0.40%) 
at ≥3 months; 
−0.28% (95% 
−0.37, −0.20%) 
at 4–12 months; 
−0.26% (95% 
−0.46, −0.06%) 
at >12 months
Not reported No 3–68 months The effect was the greatest in trials 
where providers used Web portals 
or text messaging to communicate 
with patients [mean difference: 
−0.35% (95% −0.56, −0.14) and 
−0.28% (95% CI −0.52, −0.14)] at 
4–12 months
Mixed 
participants 
with type 1 and 
2 diabetes
Alharbi et al., 
2016 [19]
Evaluating of effect 
of HITs in glycemic 
control in T2D 
patients.
HITs included Web-
based approaches, 
telephone-based 
system, mobile 
phone-based system, 
and telemedicine
RCTs 
conducted 
up until July 
2016
32 RCTs; 40,454 
participants 
with T2D
−0.33%, (95% CI 
−0.40, −0.26)
Not reported No 3–36 months Electronic self-management 
systems [mean difference: −0.50% 
(95% CI −0.67, −0.43%)]; EHR 
[mean difference: −0.33% (95% 
CI −0.40, −0.26%)]; electronic 
decision support system [mean 
difference: −0.15% (95% CI −0.34, 
−0.16%)]; diabetes registry [mean 
difference: −0.05% (95% CI −0.15, 
−0.19%)]
Did not provide 
analysis at 
different time 
points
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Author, year Objective and 
intervention(s) 
under review
Inclusion 
criteria
Sample HbA1c 
reduction 
(absolute 
difference in 
means)
HbA1c reduction 
(standardized 
difference in 
means and 
Hedges’ g)
CVD risk 
factor 
assessment
Intervention 
period
HIT subgroup analysis Major 
limitations
Pal et al., 2014 
[24]
Evaluating 
computer-based 
interventions in 
self-management in 
T2D patients.
Intervention 
delivered via clinics, 
the Internet, and 
mobile phone
RCTs 
conducted 
up until 
November 
2011
16 RCTs; 3578 
participants 
with T2D
−0.2% (95% CI 
−0.4, −0.1%)
Not reported Yes. Did 
not find 
improvement 
of blood 
pressure, 
lipids, or 
weight due to 
interventions
8 weeks to 
12 months
Mobile phone intervention (mean 
difference: −0.5%, 95% CI −0.3, 
−0.7)
Did not provide 
analysis at 
different time 
points
Marcolino 
et al., 2013 [22]
Evaluating of effect 
of telemedicine on 
diabetes care
RCTs 
conducted 
up until 
April 2012
13 RCTs; 4207 
participants 
with diabetes
−0.44% (95% CI 
−0.61, −0.26%)
Not reported Yes. Only 
found 
telemedicine 
was associated 
with reduction 
in LDL 
(−6.6 mg/dL, 
95% CI −8.3, 
−4.9 mg/dL)
6–18 months Not reported Mixed 
participants 
with type 1 and 
2 diabetes; did 
not provide 
analysis at 
different time 
points
Liang et al., 
2010 [23]
Evaluating of effect 
of mobile phone 
intervention for 
diabetes on glycemic 
control
RCTs 
conducted 
from 
January 
2010 to 
February 
2010
22 trials 
including 11 
RCTs and 11 
non-RCTs; 1657 
participants 
with diabetes
−0.5% (95% CI 
−0.3, −0.7%)
Not reported No 3–12 months Not reported Lumped 
nonrandomized 
and randomized 
trials together 
into evaluation
Table 1. 
Synthesized findings of effect of HITs on HbA1c and cardiovascular risk factors among diabetes patients.
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(n = 2), cellular/automated telephone (n = 4), Internet-based (n = 4), and tele-
medicine/telehealth (n = 3). The Internet-based interventions demonstrated the 
greatest reduction in HbA1c at both 6 months (pooled standardized difference 
in mean: −0.50, 95% CI −0.69, −0.32) and 12 months (pooled standardized dif-
ference in mean: −0.87, 95% CI −1.58, −0.21). Cellular and automated telephone 
interventions showed the smallest reduction. In Tao and colleagues’ systematic 
review on consumer-centered HITs, they identified a significant pooled reduction 
of −0.31 (95% CI −0.38, −0.23) in HbA1c from 18 RCTs [18]. Similarly, Alharbi 
et al. also found HITs were associated with a statistically significant reduction in 
HbA1c levels (mean difference: −0.33%, 95% CI −0.40, −0.26%) [19]. In addition, 
Alharbi and colleagues found studies focusing on electronic self-management 
systems demonstrated the greatest reduction in HbA1c (−0.50%), followed by 
those with electronic medical records (−0.17%), an electronic decision support 
system (−0.15%), and a diabetes registry (−0.05%) [19]. Faruque et al. identified 
11 RCTs with specific focus on effect of telemedicine [20]. Telemedicine refers to 
the use of telecommunications to deliver health services, expertise, and informa-
tion on glycemic control [20]. In this study, the authors demonstrated a significant 
reductions in HbA1c all three follow-up periods (mean difference at ≤3 months: 
−0.57%, 95% CI −0.74, −0.40%, at 4–12 months: −0.28%, 95% CI −0.37, −0.20%, 
and at >12 months: −0.26%, 95% CI −0.46, −0.06%). In another meta-analysis 
that specially focused on telemedicine, Marcolino and colleagues found telemedi-
cine was associated with a statistically significant and clinically relevant decline 
in HbA1c level compared to control (mean difference = −0.44%, 95% CI −0.61, 
−0.26%) [22]. Pal et al. examined the effect of computer-based intervention in self-
management in adults with T2D. The authors found modest effect associated with 
the interventions (mean difference: −0.2%, 95% CI −0.4, −0.1%) [24]. Liang et al. 
assessed the effect of mobile phone intervention on glycemic control in diabetes 
self-management and found a significant common reduction of HbA1c (mean 
difference: −0.5%, 95% CI −0.3, −0.7%) among 22 trials over a median follow-up 
of 6 months [23].
Many of review studies including those mentioned above have shed light on the 
effect of HITs in glycemic control. However, these studies often included limited 
number of trials [21], lack of adherence to standard quantitative methods [25], 
inadequate attention to heterogeneity across studies [26], lumped nonrandomized 
and randomized trials together into evaluation [19, 23, 25, 27–29], mixed partici-
pants with type 1 or type 2 diabetes into analysis [18, 22, 25, 27–29], or restricted 
searching criteria to a particular patient population or a specific type of HIT  
[27, 30–32]. To address these limitations and to verify if and how much HITs impact 
glycemic control, Yoshida and colleagues recently conducted a meta-analysis to 
examine the most current state of evidence from RCTs concerning the effect of 
HITs on HbA1c reduction among patients with T2D [33]. From an analysis of 34 
eligible studies (40 estimates) identified from multiple databases from January 
1946 to December 2017, the study reported that introduction of HITs to standard 
diabetes treatment resulted in a statistically reduced HbA1c. The absolute mean 
difference in HbA1c pre- and postintervention between intervention and control 
group was −0.65% (95% CI −0.99, −0.64%). The pooled reduction (standardized 
difference in means) of HbA1c was −0.57 (95% CI −0.71, −0.43) (Figure 1). In 
addition, Yoshida et al. also found the reduction was significant across each of the 
four types of HIT interventions (i.e., mobile phone-based, Web-based technologies, 
SMS/text, or others) under review, with mobile phone-based approaches generating 
the largest effects [pooled reduction was −0.67 (95% CI −0.90, −0.45)] followed by 
SMS/text [−0.64 (95% CI −1.09, −0.19)], and Web-based [−0.48 (95% CI −0.65, 
−0.30)] [33].
7Health Information Technologies in Diabetes Management
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HITs also have significant clinical impact in reducing HbA1c among patients 
with T2D. It is reported that every 1% decrease in HbA1c over a 10-year period 
is associated with a risk reduction of 21% for diabetes-related death and 37% of 
microvascular complications [34]. This reduction results from HIT interventions 
may be bigger than effects of many targeted pharmacological therapies. Oral 
antidiabetic agents reduced HbA1c levels of 0.5–1.25%, with thiazolidinedione 
and sulfonylureas showing the best reduction (1–1.25%) [35]. Biguanide reduced 
HbA1c by 1.0–2.0%; dipeptidyl peptidase 4 (DPP-IV) inhibitor, 0.5–0.8%; GLP-1 
agonists, 0.5–1.5%; and TZD, 0.5–1.4% [36]. It is questionable that the effects on 
HbA1c yielded from the HIT trials were a mixed product of both HITs and standard 
diabetes care including medication adherence and lifestyle modifications. This 
concern was addressed in the systematic review of Yoshida et al. [33]. The authors 
conducted a subset analysis of 18 studies that exclusively compared the outcome 
between a combined HITs and standard care intervention group vs. standard care 
control group. The effect size estimated from this analysis was −0.63 (Hedges’ 
g: −0.63 95% CI −0.84, −0.42), which is attributable to HIT tools in addition to the 
Figure 1. 
Pooled reduction of HbA1c due to HITs. Adopted from the study of Yoshida et al [33].
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usual care [33]. This result suggests that HITs are the key to the effectiveness rather 
than tools or components of these trials. Additionally, pharmacotherapies often 
use motivated patients’ sample and they cannot generate their full effects without 
patients’ adherence to treatment and persistence in usage [33]. In this sense, HITs 
may add additional value in the effectiveness by addressing challenges in adherence 
of a pharmacological therapy or of behavioral interventions.
4. HITs in managing cardiovascular risks among patients with T2D
T2D is commonly accompanied by cardiovascular complications. Adults with 
diabetes have a 77–87% prevalence of hypertension, a 74–81% prevalence of 
elevated low-density lipoprotein cholesterol (LDL), and a 62–67% prevalence of 
obesity [37]. Cardiovascular disease (CVD) is recognized as the most frequent 
cause of morbidity and mortality in patients with diabetes, causing up to 70% of 
all deaths in this patient group [2]. Type 2 diabetes (T2D) confers an approximate 
twofold elevation of CVD risk, equivalent to that of a previous myocardial infarc-
tion [3, 38]. In light of CVD burden in those with diabetes, the management of 
modifiable CVD risk factors, including hypertension, dyslipidemia, and obesity, is 
critical to minimizing the risk of macrovascular complications as well as death of 
diabetes. Yet, the implementation of preventive strategies to CVD among individu-
als with T2D is often not adequate [39–41] and less than half of patients who visit 
their care provider meet recommended levels for blood pressure (BP) and lipids 
[42]. Innovative approaches such as HITs are needed to facilitate CVD risk factor 
management among patients with T2D.
In the context of cardiovascular care among general populations, HITs were 
documented to offer numerous benefits and have been associated with improve-
ments in the measurement and monitoring of heart health, including risk factors 
such as BP, arrhythmia, cholesterol, and weight, as well as the implementation of 
guideline-based decision support for providers [43]. However, CVD outcomes are 
usually secondary and less described compared to glycemic status in T2D manage-
ment trials [26, 44]. Furthermore, many review studies examining HITs’ effect in 
diabetes management often overlooked CVD outcomes [26, 44] or include insuf-
ficient sample size or limited CVD parameters for analysis [22, 24]. In the study by 
Marcolino et al., only 13 studies were included in the final analysis, within which 
8 studies assessed the effect on SBP, 7 on DBP, and 5 on LDL [22]. No effects of 
telecommunication and information technologies were seen on SBP and DBP. They 
did, however, find a statistically significant reduction on LDL (−6.6 mg/dL, 95% 
CI −8.3, −4.9 mg/dL) associated with the technologies evaluated. They were not 
able to perform analysis on weight outcome, because only two studies assessed the 
effect of HITs on weight and both studies demonstrated a nonsignificant reduction 
on weight. In the systematic review by Pal et al., among 11 RCTs included in their 
final analysis, 5 studies looked into changes in BP (only 1 showed improvement in 
BP), 7 reported changes in BMI or weight (5 were combined in a meta-analysis), 
and 10 measured serum lipids (7 were combined in a meta-analysis) [24]. The over-
all pooled effect did not reach statistical significance for all of these outcomes [24].
5. Research limitations and implications
The current research on the effect of HITs in diabetes management has sev-
eral limitations. First of all, the published trials often do not provide protocols 
for studies [45]. There is also lack of information on the theoretical bases of the 
9Health Information Technologies in Diabetes Management
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interventions, and whether the HIT interventions are accompanied by other phar-
maceutical or lifestyle therapies in their publications. As these HIT interventions 
are main therapeutic agents, it would be beneficial to explicitly prescribe interven-
tions for trials and state the active components (behavior-change techniques), dose 
(frequency and intensity of interactions), route (mode of delivery), and duration of 
treatment [45]. There is also a need to clarify other ingredients in the intervention 
such as medication, standard care from health professionals, so that the major role 
of the HITs to the effectiveness of the interventions can be estimated, separating the 
effects from usual care and treatment [33].
Additionally, intervention periods in published trials are short (most trials 
under 1 year) [33] and few systematic reviews provided effect estimation by length 
of follow-up. Studies by Tao et al. and Heitkemper et al. showed that HITs’ effect on 
glycemic control was diminishing as the interventions proceeded [18, 21]. It is not 
clear whether intervention effect and compliance with the HIT interventions would 
sustain in the long term. Misuse or nonuse of technological support is a common 
problem in disease management, which greatly affects patient’s outcomes. There 
is also lack of focus on cardiovascular health assessments in HIT interventions for 
diabetes management. We only found two systematic reviews that discussed CVD 
outcomes in addition to glycemic control. Because very few trials included cardio-
vascular risk factor evaluations, the synthesized findings were modest (Table 1).  
As we discussed earlier, because CVD causes major morbidity and mortality 
among T2D patients, designing and evaluating HITs for diabetes management 
should include cardiovascular health indicators. Further, many review studies 
only reported standardized difference in means [18, 21], which may be less intui-
tive to patients who care the absolute changes (i.e., mean difference) in outcomes 
(e.g., HbA1c) due to an intervention. Moreover, it remains unclear whether there 
are harms associated with the intervention. It has been reported that people may 
suffer from negative consequences of excessive self-monitoring by finding it 
uncomfortable, intrusive, and unpleasant [46, 47]. Studies found patients with dia-
betes who self-monitor their own blood glucose concentration did not benefit from 
increased glycemic control but rather found their disease more intrusive [48]. The 
interaction between a HIT device and a patient can be complex, and further studies 
need to consider these in more detail. Further, whether the interventions would be 
cost-effective if it required significant health professional support in a long-run has 
not been documented well in the literature [33, 49]. Additional research with more 
time points of follow-up is warranted to maximize data to inform the compliance 
with the HITs, long-term impact on health outcomes, to look for evidence of harms 
and to determine the cost-effectiveness in the intervention [49]. Studies with CVD 
risk factor assessments and absolute outcome measurement are also needed.
Moreover, it is unknown which populations will benefit the most from the 
HIT intervention as the current research in HITs has not always directly engaged 
diverse end users. There are also many questions surrounding the “digital divide” 
in HITs use, where the access, usability, and effectiveness of diabetes technologies 
are divided by users’ age, education, computer literacy, culture, and affluence [49]. 
These issues highlight the importance of engaging more research to design, test, 
and implement HITs for diverse patients with diabetes.
6.  Barriers of using HITs in the real-world context and steps to move 
forward
While features of HITs can expand patients’ ability in diabetes management and 
the results from the existing research showed their positive effects on outcomes of 
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HbA1c and CVD risk factors, many of these applications described above have so far 
been explored predominantly within clinical trials rather than a real-world context. For 
those that have been widely used in real health-care setting, such as electronic patient 
record system; both health-care providers and patients have reported difficulties for 
engagement [50]. Multiple sources of tension contribute to these barriers (Table 2).
First of all, the reliability and validity of some HITs is concerning. For example, 
many manufacturers market their products under the premise that they will help in 
improving health, but they often do not provide empirical evidence to support the 
effectiveness of their products [51]. Recent comparisons between different wear-
able devices for tracking physical activities yielded large heterogeneity in accuracy 
[52, 53]. The medical apps market also showed the similar discrepancy [54]. Lack 
of reliability is a serious obstacle that needs to be addressed before a HIT could 
be considered for medical use. Moreover, whether technological designs incorpo-
rated evidence-based guidelines is questionable [55]. It is reported that features 
of diabetes management apps on the online market did not cover evidence-based 
recommendations. A recent study evaluated 137 diabetes management apps from 
two major app stores (iTunes and Google Play) and compared the features with the 
American Association of Diabetes Educators (AADE) Self-Care Behavior guide-
lines. The author found an unbalanced feature development of current diabetes 
management apps. Few apps provided features supporting problem solving, reduc-
ing risks, and healthy coping, which are critical for user engagement and successful 
diabetes self-management [56].
Secondly, the privacy and security of personal data generated by HITs remains 
problematic. Users of these devices or technologies usually do not own the data; 
rather, data may be collected and stored by the manufacturers [51]. While some 
companies are willing to share user’s “anonymizing” data via a simple distortion or 
removal of identifying features, these techniques do not provide adequate levels of 
anonymity and are not sufficient to prevent identity fraud [57]. Moreover, some 
devices are easily to be hacked as a result of various communication technologies 
that aid the transfer of data between the devices and smartphones. It has been 
reported that wireless digital pacemakers and glucose pumps are vulnerable to 
cyberattacks [58].
Further, even in relatively widely adopted HIT systems, such as the electronic 
patient records system, there are still many unfilled promises due to lack of interop-
erability between systems, difficult-to-use interface, and lack of consideration on 
patients’ backgrounds [50]. In the United States, for example, the patient records 
Barriers Possible solutions
Validity and 
reliability
• Incorporating empirical evidence into design development
• Being coherent with guidelines from credible sources
• Evaluating users’ needs and improve features on supporting problem solving, 
reducing risks, and healthy coping
Privacy and 
security
• Creating regulatory framework and risk-based classifications to promote innova-
tion, protect patient safety, and avoid regulatory duplications
Adaptability • Building interoperability between systems
• Building easy-to-use interface
• Providing incentives for engagement
• Considering users’ diverse background (language, health literacy, cultural 
preference)
Table 2. 
Barriers of using HITs in the real-world context and possible solutions.
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systems are not designed to talk to each other [59]. Until now, health-care providers 
have had little incentive to acquire or develop interoperable systems [50]. As a result, 
the current electronic health records do not allow a patient or provider to access 
needed health information anywhere at any time. Additionally, many clinicians are 
reluctant to invest the considerable time and effort to master difficult-to-use tech-
nology, which hindered the anticipated productivity gains of HITs [59]. Moreover, 
there are limited data collection on patient backgrounds, such as race/ethnicity, 
language preference, and health literacy in the patient records systems [49]. Lack of 
this set of data could cause fragmented care delivery and lead to patients’ misunder-
standing of provider instruction and lose trust in the medical system [49].
To transform HITs a real asset for diabetes care, further steps need to be con-
sidered (Table 2). First is to create a simple regulatory framework that does not 
suppress innovation but helps HITs, especially some wearable devices and apps 
become valid in the context of their health-oriented value [51]. A risk-based clas-
sification that promotes innovation, protects patient safety, and avoids regulatory 
duplications has recently been proposed [60]. As part of this model, the U.S. Food 
and Drug Administration jurisdiction covers higher-risk medical apps [61]. The 
National Health Service in the United Kingdom adopts similar pathway with their 
regulatory framework for mobile apps, which can be classified as “medical devices” 
by Medicines and Health Products Regulatory Agency [61].
A simple and powerful guide is also needed to transform the HIT system, 
especially the electronic patient records system. Health data stored in one system 
should be readily retrievable by others, subject to patient consent [50, 62]. For true 
interoperability, standardization must be achieved across three dimensions: how 
messages are sent and received; the structure and format of the information; and 
terms used within these dimensions [50]. HITs should also facilitate the work of cli-
nicians by providing a system that is intuitive to use and without extensive retrain-
ing. Easy-to-use HIT systems not only will increase the productivity of providers 
but also will be safer [50].
Additionally, HIT systems need to include automated and standardized 
categories for a patient background (e.g., race/ethnicity, language), facilitate 
communication among multiple providers and patients, and tailor to the needs 
of diverse populations [9]. Moreover, a genuine partnership should be fostered 
between patients and health-care providers through the use of HITs. Engagement 
can range from patients being simply better informed to individuals themselves 
being dynamically engaged in the HIT management, giving feedbacks about the 
HIT interventions, and even controlling who has access to their data [62, 63]. 
Furthermore, future technologies developed for diabetes management should 
incorporate balanced features from creditable guidelines to better support changing 
self-management behaviors of people with diabetes.
7. Conclusion
Overall, the current evidence shows that HITs have favorable impact on glycemic 
control and CVD risk management among patients with T2D. Future studies should 
examine the long-term effects of HITs and their cost-effectiveness, potential harms, 
and test and verify their effectiveness in glycemic control and other important 
health indicators such as CVD risk factors, among diverse populations. HITs may 
be valuable tools in enhancing human health and well-being overall. However, their 
advances also pose challenges in aspects of validity and reliability, patients’ privacy, 
security, and engagement. These issues need to be addressed before a broader 
implementation of HITs in the real-world setting.
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